Telisotuzumab Adizutecan: A Breakthrough Antibody-Drug Conjugate in Lung Cancer Therapy
Introduction : Lung cancer is one of the most challenging cancers to treat, especially in its advanced stages. As scientists and pharmaceutical companies strive for better results, one promising treatment that has garnered attention in recent years is telisotuzumab adizutecan. This antibody-drug conjugate (ADC) is making waves in clinical trials for a targeted approach to …
